在生物科技板块充满挑战的一年中，Fulgent Genetics Inc. (FLGT)股票触及52周低点，跌至18.76美元。这家以先进基因检测解决方案而闻名的公司面临重大下滑，其股价反映出一年内-30.87%的变化。这种下降凸显了该行业的一个更广泛趋势，即投资者正在重新调整他们在不断变化的医疗保健环境中的预期。尽管目前处于低点，Fulgent ...

▲ 点击上方蓝字关注CellPress细胞科学 ▲生命科学Life science近日，Cell Press细胞出版社旗下权威综述期刊Trends in Genetics发表了中国科学院深海科学与工程研究所张海滨研究员团队撰写的文章“Genetic ...

Ireland's dairy breeding index measures the genetic merit of animals based on everything from milk production to carbon ...

This trend leads one to some important questions: Are lifestyle or genetic factors playing a role in this shift? Dr. Dheeraj ...

Aryna Sabalenka enjoyed a phenomenal run in 2024, claiming multiple titles and the World No.1 ranking. Although she couldn’t ...

A new study has revealed how genetic variations in the SI gene, which affects sucrose digestion, influence dietary ...

周三，Scotiabank调整了对Myriad Genetics（NASDAQ:MYGN）的展望，将股票目标价从之前的34.00美元下调至24.00美元。尽管下调了目标价，但该公司仍维持对该股票的"板块跑赢大盘"评级。此次价格调整是对联合健康集团（UNH）最近政策变更的回应，该政策将从2025年1月1日起 ...

Political scientist Kevin Smith says his research suggests “political orientations are at least partially under genetic ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

Adjusted EPS was $0.31, significantly above the expected loss. The company is encouraged by preliminary results in testing ...

而在财报发布的当日，Tempus宣布，将以6亿美元（折合人民币约为43亿，分为3.75亿美元现金和2.25亿美元股票）的价格收购具有25年发展历史的IVD企业Ambry Genetics。该笔收购预计将于2025年*季度完成。

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.